Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

A framework for assessing therapeutic innovation

¹Cancer Centre, Clinique de Genolier, Switzerland.

Anti-Cancer Drugs

|December 1, 1993

Summary

Budgetary limits impact medical prescriptions. A cost-benefit analysis shows 5-HT3 receptor antagonists are best for acute emesis, with careful evaluation for other uses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Same author

[Society face to cancer: awareness and social actions].

Revue medicale suisse·2015

Same author

Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?

Cancer treatment reviews·2012

Same author

What do prescribers think of biosimilars?

Targeted oncology·2012

Same author

Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.

Annals of oncology : official journal of the European Society for Medical Oncology·2011

Same author

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

European journal of cancer (Oxford, England : 1990)·2010

Area of Science:

Pharmacoeconomics
Clinical decision-making
Gastroenterology

Background:

Budgetary constraints increasingly influence medical prescription practices.
Evaluating the cost-effectiveness of new medical interventions is crucial.
Existing treatments for emesis may not always be cost-efficient.

Purpose of the Study:

To propose a straightforward method for evaluating the costs and benefits of medical interventions.
To determine the appropriate use of 5-HT3 receptor antagonists based on cost-benefit analysis.
To guide clinical decisions regarding the adoption of new treatments under financial limitations.

Main Methods:

Defining and comparing the efficacy of a new approach against the best existing care.
Calculating the incremental gain in efficacy relative to the true costs of both procedures.
Utilizing detailed cost-benefit and quality of life studies for debatable cases.

Main Results:

The proposed approach prioritizes innovations with high efficacy gains and low or minimally increased costs.
Cost-benefit and quality of life studies are essential when efficacy gains and costs are not clearly favorable.
5-HT3 receptor antagonists demonstrate a favorable cost-benefit profile primarily for the acute phase of emesis.

Conclusions:

A simple cost-benefit evaluation framework can guide prescription decisions under budgetary restraints.
The current evidence suggests 5-HT3 receptor antagonists should be reserved for managing acute emesis.
Further detailed analyses are required to justify the use of these agents in other scenarios.

Related Experiment Videos